ADMA Biologics, Inc. (ADMA) vs BioCryst Pharmaceuticals, Inc. (BCRX)

A side-by-side comparison of ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ADMA vs BCRX

growth of $100 · dividends reinvested · last 10y
ADMA +50.9% (+4.2%/yr)BCRX +78.8% (+6.0%/yr)BCRX compounded faster over this window
0100200300400Start $10020182020202220242026$151$179
ADMA BCRX

ADMA vs BCRX: by the numbers

  • •ADMA is the larger company ($2.36B vs $2.04B market cap).
  • •ADMA is profitable (32.98% net margin) while BCRX runs a net loss (-40.90%).
  • •BCRX grew revenue faster over the past five years (64.07% vs 54.55% CAGR).

Metrics side by side

Valuation

MetricADMABCRX
P/E ratio14.54N/A
Forward P/E12.78N/A
P/S ratio4.612.17
P/B ratio5.78N/A
EV / EBITDA10.74N/A
FCF yield4.94%17.51%

Profitability

MetricADMABCRX
Gross margin64.71%97.82%
Operating margin42.26%38.98%
Net margin32.98%-40.90%
ROE41.39%N/A
ROIC27.60%-89.73%

Growth (annualized)

MetricADMABCRX
Revenue CAGR (5Y)54.55%64.07%
Total return CAGR (5Y)54.74%-10.02%

Frequently asked

Which has grown faster, ADMA or BCRX?
Over the past five years, BCRX grew revenue faster — ADMA at a 54.55% CAGR versus BCRX at 64.07%.
Is ADMA or BCRX more profitable?
ADMA runs the higher net margin — ADMA at 32.98% versus BCRX at -40.90%.
How have ADMA and BCRX total returns compared?
Over the past 10 years, ADMA delivered 3.85% and BCRX delivered 5.82% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.